Zystor
Privately-held biotechnology company developing enzyme replacement therapies for the treatment of lysosomal.
Launch date
Employees
Market cap
-
Enterprise valuation
€105m (Public information from Aug 2010)
Milwaukee Wisconsin (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
$8.5m | Series A | ||
$115m Valuation: $115m | Acquisition | ||
| Total Funding | €7.7m | ||